Forsys Metals Corp.

Condensed Interim Consolidated Financial Statements (Revised) June 30, 2021

(expressed in Canadian dollars) (unaudited)

Note to Reader

The unaudited condensed interim consolidated financial statements for the 6 months ended June 30, 2021 filed on SEDAR on August 13, 2021 did not include the financial statements. These revised unaudited condensed interim consolidated statements for the 6 months ended June 30, 2021 have been revised to include the financial statements. Both documents will remain on SEDAR.

Management's Comments on Unaudited Condensed Interim Consolidated Financial Statements

These unaudited condensed interim consolidated financial statements of Forsys Metals Corp. (the "Company") have been prepared by management and approved by the Board of Directors of the Company.

These unaudited condensed interim consolidated financial statements have not been reviewed by the Company's external auditors.

Forsys Metals Corp. Consolidated Statement of Financial Position

(expressed in Canadian dollars) (unaudited)

		2021	As at December 31, 2020
	Notes	\$	\$
Assets			
Current			
Cash and cash equivalents		12,436,713	876,967
Receivables		40,373	26,031
Prepaid expenses and other assets		30,897	20,489
		12,507,983	923,487
Non-current			
Investment in associate	4	2,572,459	2,573,967
Exploration and evaluation	5	10,713,600	10,698,359
Total assets		25,794,042	14,195,813
List Webs			
Liabilities Current			
Accounts payable and accrued liabilities		453,084	142,808
Accounts payable and accided liabilities		433,004	142,000
Shareholders' equity			
Share capital	6	172,075,571	165,838,742
Warrants	7	6,796,733	1,300,733
Contributed surplus		46,987,780	44,449,715
Equity reserve		33,364	33,364
Accumulated loss		(183,476,861)	(180,458,038)
Accumulated other comprehensive loss		(17,079,971)	(17,115,896)
Total equity attributable to shareholders of the Company		25,336,616	14,048,620
Non-controlling interest	9	4,342	4,385
Total equity		25,340,958	14,053,005
Total liabilities and equity		25,794,042	14,195,813

On behalf of the Board:

Martin Rowley

Director

Mark Frewin **Director**

Forsys Metals Corp. Consolidated Statement of Loss and Comprehensive Loss

(expressed in Canadian dollars) (unaudited)

	Notes	3 months e 2021 \$	nded June 30, 2020 \$	6 months e 2021 \$	nded June 30, 2020 \$
Expenses					
Professional fees		26,316	25,275	61,215	48,295
Directors' fees and benefits		94,471	56,825	126,471	81,280
Consulting fees		100,881	72,775	146,631	127,098
Stock-based compensation	8	2,585,000	-	2,585,000	-
Public company costs		56,478	5,647	90,074	35,565
General and administrative		3,972	4,793	8,401	9,529
Foreign exchange loss (gain)		(9)	56	1,074	(1,031)
Interest income		_	-	-	(1,296)
		2,867,109	165,371	3,018,866	299,440
		(0.007.400)	(405.074)	(0.040.000)	(000 440)
Loss		(2,867,109)	(165,371)	(3,018,866)	(299,440)
Other comprehensive loss, net of taxes					
Item that may be reclassified subsequently to loss		007.654	(474.046)	25.025	(2.205.474)
Foreign currency translation		237,654 (2,629,455)	(171,216)	35,925 (2,982,941)	(2,205,174)
Comprehensive loss		(2,029,455)	(336,587)	(2,902,941)	(2,504,614)
Net loss attributable to:					
Shareholders of the Company		(2,867,109)	(165,371)	(3,018,823)	(299,440)
Non-controlling interest	9	(2,001,100)	(100,011)	(43)	(200, 110)
- Tron some simily interest		(2,867,109)	(165,371)	(3,018,866)	(299,440)
				,	7
Comprehensive loss attributable to:					
Shareholders of the Company		(2,629,455)	(336,587)	(2,982,898)	(2,504,614)
Non-controlling interest	9	-	-	(43)	
		(2,629,455)	(336,587)	(2,982,941)	(2,504,614)
Loss per share		(4.52)	(0.40)	(4.74)	(0.10)
- basic and diluted (cents)		(1.53)	(0.10)	(1.71)	(0.18)
Weighted average number of					
common shares outstanding		186,957,159	166,899,467	177,012,408	165,635,731
- Common ondition outcomming				,0.12,100	

Forsys Metals Corp. Consolidated Statement of Changes in Equity

(expressed in Canadian dollars) (unaudited)

Share capital Share capital 6 165,838,742 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 164,847,132 167,838,742 164,847,132 164,444,447,153 164,444,447,153 164,444,447,153 164,444,447,153 164,444,447,153 164,444,447,153 164,444,447,153 164,444,444,447,153 164,444,444,447,153 164,444,444,4			6 months e 2021	nded June 30, 2020
Balance, beginning of period 166,838,742 64,847,132 Bought deal equity financing 6 13,000,000		Notes		_
Bought deal equity financing 6 13,000,000 - Fair value of broker warrants issued 6 and 7 (759,000) - Fair value of broker warrants issued 6 and 7 (759,000) - Private placement of Class A shares (1,373,606) (7,890) Share issue costs 59,500 - Exercise of stock options 46,935 - Fair value of exercised stock options 13,00,733 1,300,733 Fair value of operiod 1,300,733 1,300,733 Fair value of unit warrants issued 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, beginning of period 6 and 7 759,000 - Eair value of broker warrants issued 4 and 7 4,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of period 8 2,585,000 - Equity reserve 8 1,693,780 44,49,715 Balance, beginning and end of period 33,364 33,364				
Fair value of unit warrants issued 6 and 7 (75,000) - Fair value of broker warrants issued 6 and 7 (75,000) - Private placement of Class A shares 1,000,000 Share issue costs (1,373,606) (7,890) Exercise of stock options 59,500 - Fair value of exercised stock options 46,935 - Balance, end of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4,737,000 - Fair value of unit warrants issued 6 and 7 759,000 - Fair value of broker warrants issued 6 and 7 759,000 - Fair value of period 4,444,715 44,449,715 Balance, beginning of period 4,444,9715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options 46,935) - Equity reserve Balance, end of period 33,364 33,364 Balance, beginning and end of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440)				164,847,132
Fair value of broker warrants issued 6 and 7 (759,000) - 1 Private placement of Class A shares 1,000,000 1,000,000 Share issue costs 1,373,600 7,890 Exercise of stock options 59,500 - 2 Fair value of exercised stock options 172,075,571 165,839,242 Warrants Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4737,000 - 6 Fair value of broker warrants issued 6 and 7 4737,000 - 6 Fair value of broker warrants issued 6,796,733 1,300,733 Balance, end of period 4,4449,715 44,449,715 Stock-based compensation 8 2,585,000 - 6 Fair value of exercised stock options 46,935,780 44,449,715 Balance, beginning of period 33,364 33,364 33,364 Accumulated loss (1,000) 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000	• • • •			-
Private placement of Class A shares 1,000,000 Share issue costs (1,373,606) (7,890) Exercise of stock options 59,500 - Bain value of exercised stock options 46,935 - Balance, end of period 1,300,733 1,300,733 Balance, beginning of period 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 4,4449,715 44,449,715 <td></td> <td></td> <td>,</td> <td>-</td>			,	-
Share issue costs (1,373,606) (7,800) Exercise of stock options 59,500 - Fair value of exercised stock options 46,935 - Balance, end of period 172,075,571 165,839,242 Warrants Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4737,000 - Fair value of broker warrants issued 6 and 7 75000 - Balance, end of period 6 and 7 75000 - Balance, beginning of period 44,449,715 44,449,715 44,449,715 5100,733 1,300,733 1,444,49,715 44,449,715 44,449,715 44,449,715		6 and 7	(759,000)	-
Exercise of stock options 59,500 - a fair value of exercised stock options - a fair value of unit warrants issued - a fair value of broker warrants issued 6 and 7 a fair value of exercised stock options - a fai	·		-	
Fair value of exercised stock options 46,935 - Balance, end of period 172,075,571 165,839,242 Warrants Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issued 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 6,796,733 1,300,733 Contributed surplus Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options 46,935 - Balance, end of period 46,987,780 44,449,715 Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (2,994,40) Balance, beginning of period (183,476,861) (179,993,780) Currency translation differences on foreign operations 35,925			•	(7,890)
Balance, end of period 172,075,571 165,839,242 Warrants Balance, beginning of period 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 1,300,733 2,250,000 - Eal residual of period of perio	·			-
Warrants Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 6,796,733 1,300,733 Contributed surplus 8 2,585,000 - Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 33,364 33,364 Equity reserve 333,364 33,364 Balance, beginning and end of period 33,364 33,364 Accumulated loss 33,364 33,364 Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993780) Accumulated other comprehensive loss (17,1079,971) (18,403,403) Balance, beg	<u>'</u>			-
Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 6,796,733 1,300,733 Contributed surplus 8 2,585,000 - Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve 8 2,585,000 - Balance, beginning and end of period 33,364 33,364 Accumulated loss 8 33,364 33,364 Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, beginn	Balance, end of period		172,075,571	165,839,242
Balance, beginning of period 1,300,733 1,300,733 Fair value of unit warrants issied 6 and 7 4,737,000 - Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 6,796,733 1,300,733 Contributed surplus 8 2,585,000 - Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve 8 2,585,000 - Balance, beginning and end of period 33,364 33,364 Accumulated loss 8 33,364 33,364 Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, beginn	Warrants			
Fair value of unit warrants issied 6 and 7 (50,000) - 2 (50,000) - 3 (50,000)			1 300 733	1 300 733
Fair value of broker warrants issued 6 and 7 759,000 - Balance, end of period 6,796,733 1,300,733 Contributed surplus 44,449,715 44,449,715 Balance, beginning of period 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve 33,364 33,364 Balance, beginning and end of period 33,364 33,364 Loss attributed to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss 8 35,925 (2,205,174) Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 8 4,385 (169,376) Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accum		6 and 7		1,300,733
Balance, end of period 6,796,733 1,300,733 Contributed surplus Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 8 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031				-
Contributed surplus Balance, beginning of period 44,449,715 44,449,715 Stock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) - 1		0 and 7		1 300 733
Balance, beginning of period 44,449,715 44,449,715 5tock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	balance, end of period		0,730,733	1,500,755
Balance, beginning of period 44,449,715 44,449,715 5tock-based compensation 8 2,585,000 - Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	Contributed surplus			
Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) - 175,031			44,449,715	44,449,715
Fair value of exercised stock options (46,935) - Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) - 175,031	Stock-based compensation	8	2,585,000	-
Balance, end of period 46,987,780 44,449,715 Equity reserve Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	·		(46,935)	-
Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	Balance, end of period			44,449,715
Balance, beginning and end of period 33,364 33,364 Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -				
Accumulated loss Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	· ·			
Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	Balance, beginning and end of period		33,364	33,364
Balance, beginning of period (180,458,038) (179,694,340) Loss attributable to shareholders of the Company (3,018,823) (299,440) Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	A a supportate d I a a a			
Loss attributable to shareholders of the Company Balance, end of period Accumulated other comprehensive loss Balance, beginning of period Currency translation differences on foreign operations Balance, end of period (17,115,896) (16,198,230) Currency translation differences on foreign operations Balance, end of period Non-controlling interest Balance, beginning of period A,385 (169,376) Reallocation of NCI share of accumulated losses Loss attributed to NCI (43)			(400, 450, 000)	(470.004.040)
Balance, end of period (183,476,861) (179,993,780) Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -			•	,
Accumulated other comprehensive loss Balance, beginning of period (17,115,896) (16,198,230) Currency translation differences on foreign operations 35,925 (2,205,174) Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	·			
Balance, beginning of period Currency translation differences on foreign operations Balance, end of period Non-controlling interest Balance, beginning of period Reallocation of NCI share of accumulated losses Loss attributed to NCI (17,115,896) (16,198,230) (2,205,174) (17,079,971) (18,403,404) (17,079,971) (18,403,404)	Balance, end of period		(183,476,861)	(179,993,780)
Balance, beginning of period Currency translation differences on foreign operations Balance, end of period Non-controlling interest Balance, beginning of period Reallocation of NCI share of accumulated losses Loss attributed to NCI (17,115,896) (16,198,230) (2,205,174) (17,079,971) (18,403,404) (17,079,971) (18,403,404)	Accumulated other comprehensive loss			
Currency translation differences on foreign operations35,925(2,205,174)Balance, end of period(17,079,971)(18,403,404)Non-controlling interestBalance, beginning of period4,385(169,376)Reallocation of NCI share of accumulated losses-175,031Loss attributed to NCI(43)-	•		(17.115.896)	(16.198.230)
Balance, end of period (17,079,971) (18,403,404) Non-controlling interest Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -			,	,
Non-controlling interest Balance, beginning of period Reallocation of NCI share of accumulated losses Loss attributed to NCI 4,385 (169,376) - 175,031				
Balance, beginning of period 4,385 (169,376) Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -			(, , - ,	(-,, - ,
Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	Non-controlling interest			
Reallocation of NCI share of accumulated losses - 175,031 Loss attributed to NCI (43) -	Balance, beginning of period		4,385	(169,376)
Loss attributed to NCI (43) -	Reallocation of NCI share of accumulated losses		-	
	Loss attributed to NCI		(43)	-
	Balance, end of period			5,655

Forsys Metals Corp. Consolidated Statement of Cash Flows

(expressed in Canadian dollars) (unaudited)

			ded June 30,
	Notes	2021 \$	2020 \$
Cash (used in)		•	•
Operating activities			
Loss		(3,018,866)	(299,440)
Item not affecting cash		,	,
Stock-based compensation	8	2,585,000	-
Changes in non-cash operating working capital			
Receivables		(14,342)	(839)
Prepaid expenses and other assets		(10,408)	13,231
Accounts payable and accrued liabilities		310,275	(78,116)
Total cash outflow from operating activities		(148,340)	(365,164)
Financing activities			
Bought deal equity financing	6	13,000,000	-
Private placement of Class A shares		-	1,000,000
Share issue costs		(1,373,606)	(8,390)
Exercise of stock options		59,500	-
Total cash inflow from financing activities		11,685,894	991,610
Investing activities			
Exploration and evaluation		(20,947)	(2,435)
Total cash outflow from investing activities		(20,947)	(2,435)
Net increase in cash		11,516,607	624,011
Cash and cash equivalents, beginning of period		876,967	712,652
Effects of exchange rate changes on cash		43,139	(106,777)
Cash and cash equivalents, end of period		12,436,713	1,229,886

Forsys Metals Corp. Notes to Condensed Interim Consolidated Financial Statements June 30, 2021

(expressed in Canadian dollars) (unaudited)

1. Nature of operations

Forsys Metals Corp. and its subsidiary companies (collectively the "Company") are engaged in the acquisition, exploration and development of mineral properties located in Namibia, Africa. The Company's principal focus is on bringing its whollyowned Norasa Uranium Project ("Norasa") into production. Norasa is the consolidation of the Valencia and Namibplaas Uranium Projects.

The Company's principal wholly-owned subsidiaries are as follows:

- Namibian Metals Ltd., a British Virgin Islands based holding company which owns 100% of the ordinary shares of Valencia Uranium (Proprietary) Limited, a Namibia based exploration company, which holds a 100% interest in the Valencia Uranium Project;
- Dunefield Mining Company (Proprietary) Limited, a Namibia based exploration company, which holds a 100% interest in the Namibplaas Uranium Project; and
- Namibian Westport Ltd., an Ontario based holding company which owns all the ordinary shares of Westport Resources Namibia (Proprietary) Ltd., a Namibian based holding company which owns 51% of the ordinary shares in Razorback Gold Mining Company (Proprietary) Limited ("Razorback") which holds a 100% interest in the Ondundu Gold Project exploration licence. Westport Resources Namibia (Proprietary) Ltd. also owns 70% of the ordinary shares in subsidiary, Omatjete Mining Company (Proprietary) Ltd.

As an exploration stage company, the Company's income is limited to interest income and other incidental income. The recoverability of the amount shown for mineral properties, exploration and evaluation costs is dependent upon, but not limited to: the existence and economic recovery of mineral reserves in the future; the ability to obtain necessary permits and financing to complete the exploration and development of these properties; government policies and regulations; and attaining profitable production or proceeds from the disposition of properties. The Company may be adversely affected by governmental amendments or changes to mining laws, regulations and requirements in Namibia.

The Company's continued operations are dependent on its ability to secure additional equity capital, divest assets or generate cash flow from operations in the future, none of which is assured.

The Company is incorporated under the Business Corporations Act (Ontario) and the primary listing of its common shares is on the Toronto Stock Exchange, with secondary listings on the Namibian Stock Exchange and Frankfurt Stock Exchange. The Company's registered office is at 20 Adelaide Street East, Suite 200, Toronto, Ontario, Canada, M5C 2T6.

2. Going concern

These condensed interim consolidated financial statements are prepared on the going concern basis which assumes the continuity of normal business activity and the realization of assets and settlement of liabilities in the normal course of business.

For the 6 months ended June 30, 2021, the Company incurred a loss of \$3,018,866 (2020: \$299,440) and a cash outflow from operating activities of \$147,967 (2020: \$365,164). On April 21, 2021, the Company completed a bought deal equity financing of \$13,000,000 ("Bought Deal Equity Financing", see note 6) and as of June 30, 2021, the Company had working capital of \$12,054,899 (December 31, 2020: \$780,679) including cash and cash equivalents of \$12,436,713 (December 31, 2020: \$876,967). The Company is in the exploration stage and does not generate revenue. In addition to the proceeds of the Bought Deal Equity Financing, the development of Norasa will require further funding. The ability of the Company to continue as a going concern is principally dependent upon its ability to secure funds by raising capital from equity markets or by other means, and by managing cash flows in line with available funds, and/or the successful development of its exploration assets.

The outbreak of the COVID-19 pandemic and the measures adopted by governments to mitigate the spread of the pandemic have not significantly impacted the Company. To date, there has been no significant impact on the Company, however, there is significant uncertainty over the impact of the pandemic on the Company's ability to secure funds in the future. These conditions indicate a material uncertainty that may cast significant doubt about the ability of the Company to continue as a going concern.

The Board of Directors are confident of the ability of the Company to raise capital as and when required, which was demonstrated by the Company completing the Bought Deal Equity Financing. The Board of Directors are satisfied there are sufficient funds to meet the Company's working capital requirements as at the date of this report.

The Board of Directors have reviewed the business outlook and the assets and liabilities of the Company and are of the opinion that the going concern basis of accounting is appropriate as they believe the Company will continue to be successful in securing additional funds as and when the need to raise funds arises.

Should the Company not be able to continue as a going concern, it may be required to realize its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements and that the financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the entity not continue as a going concern.

3. Basis of presentation

Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting*, using accounting policies consistent with International Financial Reporting Standards and its interpretations adopted by the International Accounting Standards Board.

The accounting policies used in these condensed interim consolidated financial statements are consistent with those disclosed in the Company's audited consolidated financial statements for the year ended December 31, 2020.

These condensed interim consolidated financial statements do not include certain information and disclosures normally included in annual financial statements prepared in accordance with IFRS and should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2020.

These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors on August 13, 2021.

4. Investment in associate - Ondundu Gold Project

The Ondundu Exclusive Prospecting Licence ("EPL 3195") for base, rare and precious metal exploration is held 100% by Razorback Gold Mining Company (Pty) Limited ("Razorback"). Razorback is a 51% owned subsidiary of Westport Resources Namibia (Pty) Ltd. ("Westport"), which is a wholly-owned subsidiary of the Company. On February 4, 2021, EPL 3195 was renewed for a further 2-year term.

On August 31, 2015, Omajete Mining Company (Proprietary) Limited, a 70% owned subsidiary of Westport executed a Heads of Agreement Earn-in on EPL 3195 with B2Gold Mining Investments Limited and B2Gold Namibia (Proprietary) Limited (together "B2Gold"). On January 11, 2016, an Amended and Restated Heads of Agreement Earn-In was executed replacing the original agreement and the deadlines for the 75% earn-in and call option for the balance of the shares in Razorback were both extended by letter agreement dated October 2, 2018. The Company was paid an Earn-in extension fee of US\$150,000 in 2018 and a further payment of US\$100,000 in 2019 ("Extension Fees").

The Earn-In gives B2Gold the option to earn up to a 100% interest in EPL 3195. On January 1, 2018, B2Gold earned a 49% interest in Razorback by making cumulative expenditures of US\$2,000,000. B2Gold had the option to increase its interest to 75% by making expenditures of US\$1,300,000 by November 30, 2020 and by making a subsequent election to increase its shareholding ("Election"). While B2Gold incurred the requisite expenditures, B2Gold decided not to make the Election, but retains a call option exercisable to January 2, 2022 to increase its existing shareholding in Razorback to 100%. The consideration for exercise of this call option is US\$8,500,000 less the Extension Fees and other payments made by B2Gold to buy-out interests in EPL 3195 amounting to US\$434,000. The consideration can be a 100% cash payment or, at B2Gold's option, 50% cash payment with the balance paid by the issue of B2Gold common shares based on a 5-day VWAP prior to the exercise date.

If B2Gold withdraws from the agreement, B2Gold will transfer to Westport all ordinary shares held by B2Gold in Razorback for nil consideration. Westport would then hold 100% of the shares in Razorback.

Although the Company holds a 51% interest in Razorback, on November 21, 2018, the Company determined that it no longer had the ability to direct the relevant activities that significantly affect the returns of Razorback. As of that date, the Company accounted for its interest in Razorback using the equity method and exploration and evaluation related to Ondundu and non-controlling interest in Razorback were reclassified to interest in associate.

12,155,901

Balance at June 30, 2021	2,572,459
Foreign exchange movement	(1,508)
Balance at December 31, 2020	2,573,967

Summarized statement of financial position of Razorback

	As at June 30, 2021 \$	As at December 31, 2020 \$
Assets		
Current assets		
Cash		265,408
Value added tax receivable		18,113
		283,520
Exploration and evaluation		12,150,064
		12,433,584
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities		3,595
Due to B2Gold		274,087
		277,683

Summarized statement of loss and comprehensive loss for the 6 months ended June 30, 2021 Razorback had no revenues or expenses for the 6 months ended June 30, 2021.

Reconciliation to carrying amount

Net assets

Reconciliation to carrying amount	As at June 30, 2021	As at December 31, 2020
Company's share percentage ownership of Razorback	51%	51%
	\$	\$
Company's share of net assets of Razorback	6,199,510	6,122,826
Equity contributed by B2Gold	3,627,061	3,548,859
Carrying amount of investment in Razorback	2,572,459	2,573,967

5. Exploration and evaluation

	\$
Norasa	
Balance at December 31, 2020	10,698,359
Additions to exploration and evaluation	20,947
Foreign exchange movement	(5,706)
Balance at June 30, 2021	10,713,600

Norasa Uranium Project

The Norasa Uranium Project is the consolidation of the Valencia Uranium Project and the Namibplaas Uranium Project in Namibia.

Valencia Uranium Project

Through its wholly owned subsidiary Valencia Uranium (Proprietary) Limited, the Company holds Mining Licence ML149 for the Valencia Uranium Project. This Mining Licence was granted effective June 23, 2008 for a period of 25 years until June 22, 2033.

Namibplaas Uranium Project

The Exclusive Prospecting Licence ("EPL") 3638 for Namibplaas is held by Dunefield Mining Company (Proprietary) Limited which is a wholly owned subsidiary of the Company. Following acceptance of terms on September 21, 2020, EPL 3638 was renewed until September 20, 2022.

Impairment

At June 30, 2021 and December 31, 2020, the Board reviewed the carrying value of the capitalized exploration and evaluation of Norasa. The Board considered the impairment indicators contained within IFRS 6 and concluded that no impairment indicators have been identified.

6. Share capital

Authorized

An unlimited number of Class A common shares without par value

An unlimited number of redeemable, voting non-participating Class B shares

An unlimited number of Class C shares with rights and privileges to be determined by the Company's Board of Directors

Issued

Sildle's \$		Number of Class A common shares	Amount \$
Balance, December 31, 2020 166,899,467 165,838,742	Balance, December 31, 2020	166,899,467	165,838,742
Bought deal equity financing 26,000,000 13,000,000	Bought deal equity financing	26,000,000	13,000,000
Fair value of unit warrants – (4,737,000	Fair value of unit warrants	-	(4,737,000)
Fair value of broker warrants – (759,000	Fair value of broker warrants	-	(759,000)
Share issue costs – (1,373,606	Share issue costs	-	(1,373,606)
Exercise of stock options 350,000 59,500	Exercise of stock options	350,000	59,500
Fair value of exercised stock options – 46,935	Fair value of exercised stock options	-	46,935
Balance, June 30, 2021 193,249,467 172,075,571	Balance, June 30, 2021	193,249,467	172,075,571

The Company has not issued any Class B or Class C shares.

Bought deal equity financing

On April 21, 2021, the Company completed a bought deal equity financing of 26,000,000 units at a price of \$0.50 per unit for gross proceeds of \$13,000,000. Each unit consisted of one common share and one-half of one unit warrant, with each whole unit warrant entitling the holder to purchase one common share for \$0.75 until April 21, 2023. In connection with the financing, the Company paid a cash commission of \$910,000 and issued 1,820,000 broker warrants entitling the holder to purchase one common share for \$0.57 until April 21, 2023.

The fair value of the unit warrants and broker warrants was calculated using the Black-Scholes option pricing model with the following assumptions:

	Unit warrants	Broker warrants
Issue date	April 21, 2021	April 21, 2021
Expiry date	April 21, 2023	April 21, 2023
Warrants issued	13,000,000	1,820,000
Exercise price	\$0.75	\$0.57
Share price	\$0.75	\$0.75
Risk-free interest rate	0.30%	0.30%
Expected volatility based on historical volatility	92%	92%
Expected life of warrants	2 years	2 years
Expected dividend yield	0%	0%
Fair value	\$4,737,000	\$759,000
Fair value per warrant	\$0.36	\$0.42

7. Warrants

A summary of the Company's common share warrants outstanding at June 30, 2021 is presented below:

	Expiry date	Weighted-average exercise price \$	Number of warrants
Balance, December 31, 2020 Issued		_	_
Unit warrants	April 21, 2023	0.75	13,000,000
Broker warrants	April 21, 2023	0.57	1,820,000
Balance, June 30, 2021		0.73	14,820,000

8. Stock options

The Company has established a stock option plan to provide additional incentive to its officers, directors, employees and consultants for their efforts on behalf of the Company in the conduct of its affairs. Under this stock option plan, as amended in 2008, the Company is authorized to grant a maximum of 12,000,000 stock options to its directors, officers, employees and consultants to acquire Class A common shares. At June 30, 2021, 4,291,666 stock options have been exercised since 1998 and 7,700,000 stock options are outstanding (net of forfeitures and cancellations) leaving 8,334 stock options to be granted (December 31, 2020: 4,008,334).

The term of any stock options granted is five years from the date of issue and the exercise price of any stock option granted shall not be lower than the market price of the Company's Class A common shares on the date on which the grant of the stock option is approved by the Board of Directors. The Board of Directors determines the number of stock options, the date or dates on which the options should be granted and the terms and conditions attached to each stock option within the limits prescribed by applicable law.

A summary of the activity in the Company's stock option plan is presented below:

	Weighted- average exercise price \$	Number of stock options outstanding and exercisable
Balance, December 31, 2020	0.17	4,050,000
Granted	0.93	4,000,000
Exercised	0.17	(350,000)
Balance, June 30, 2021	0.56	7,700,000

A summary of the Company's stock options outstanding and exercisable as at June 30, 2021 is presented below:

		Number of stock options outstanding and
Exercise price	Expiry date	exercisable
\$0.17	October 9, 2024	3,700,000
\$0.93	May 20, 2026	4,000,000
		7,700,000

Grant of stock options

A summary of the stock options granted to directors, officers and a consultant and the assumptions for the calculation of the fair value of those stock options using the Black-Scholes option pricing model is presented below:

Date of grant	May 20, 2021
Expiry date	May 20, 2026
Stock options granted	4,000,000
Exercise price	\$0.93
Share price	\$0.93
Risk-free interest rate	0.94%
Expected volatility based on historical volatility	90%
Expected life of stock options	5 years
Expected dividend yield	0%
Forfeiture rate	0%
Vesting	On date of grant
Fair value	\$2,585,000
Fair value per stock option	\$0.65

9. Non-controlling interest

9

Balance, December 31, 2020	4,385
Loss attributed to non-controlling interest	(43)
Balance, June 30, 2021	4,342

10. Fair value measurement

The Company's principal financial instruments are cash and cash equivalents, receivables and trade payables. Financial instruments are classified into one of five categories: assets and liabilities held at fair value through profit and loss, held-to maturity investments, loans and receivables, available-for-sale financial assets and other financial liabilities. The carrying values of the Company's financial instruments are classified into the following categories:

	June 30, 2021 \$	December 31, 2020 \$
Recurring measurements		
Financial assets		
Cash and cash equivalents and receivables	12,477,086	902,988
Financial liabilities		
Accounts payable and accrued liabilities	453,082	142,808

Each level is based on the transparency of the inputs used to measure the fair values of assets and liabilities:

- Level 1 Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities,
- Level 2 Values based on quoted prices in markets that are not active or model inputs which are observable either directly or indirectly for substantially the full term of the asset or liability,
- Level 3 Values based on prices or valuation techniques that require inputs which are both unobservable and significant to the overall fair value measurement.

The Company applies a fair value measurement hierarchy to assets and liabilities in the consolidated statement of financial position carried at fair value.

A number of the Company's accounting policies and disclosures require the determination of fair values for both financial assets and non-financial assets and liabilities. The fair value has been determined for measurement and/or disclosure purposes based on the methods described below. Where applicable, additional information on the assumptions used to determine fair value is included in the notes related to the specific asset or liability.

Financial risk management

The Company's activities expose it to a variety of risks arising from financial instruments. These risks, and management's objectives, policies and procedures for managing these risks, are discussed below.

i) Credit risk

Credit risk is the risk of loss associated with a counter party's inability to fulfil its payment objectives. The Company's credit risk primarily relates to cash and cash equivalents.

The Company manages its credit risk over cash and cash equivalents by purchasing short-term investment grade securities, such as banker's acceptances and bank deposit notes issued by Canadian banks. Under the Company's risk management policy, allowable counterparty exposure limits are determined by the level of the rating unless exceptional circumstances apply. A rating of "A"- grade or equivalent is the minimum allowable rating required as assessed by international credit rating agencies.

ii) Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial liabilities as they come due. The Company's approach to managing its liquidity risk is to prepare company-wide rolling cash forecasts to determine the funding required to support the Company's normal operating activities on an ongoing basis. At June 30, 2021, the Company had cash and cash equivalents of \$12,436,713 (December 31, 2020: \$876,967), receivables of \$40,052 (December 31, 2020: \$26,031) and financial liabilities consisting of accounts payable and accrued liabilities of \$453,082 (December 31, 2020: \$142,808).

iii) Market risk

Market risk is the risk that changes in market price, foreign exchange rates and interest rates will affect the Company's future cash flows and earnings. The impact of each of these components is discussed below.

Price risk - The Company is not exposed to equity securities price risk.

Interest rate risk - Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. At June 30, 2021, the Company's exposure to the risk of changes in market interest rates relates primarily to the Company's cash and cash equivalents held in bank accounts that earn variable interest rates. Because of the short-term nature of these financial instruments, fluctuations in market rates do not have a significant impact on estimated fair values at June 30, 2021. Future cash flows from interest income on cash will be affected by interest rate fluctuations. Future fluctuations in interest rates will impact the Company's cost of capital which it will require in order to develop its mineral properties.

Foreign currency risk - The Company's foreign currency exposures currently related to the currency in which expenses for exploration and development occur. Future profitability may be materially impacted by fluctuations between the Namibian dollar in which production costs will be incurred and the US dollar in which most sales of uranium occur. The Company retains substantially all of its cash with its parent in Canadian dollars until it is required by its foreign subsidiaries. Expenses are incurred in Canadian dollars, United States dollars, Namibian dollars, Australian dollars, Euros and British Pounds. The Company is subject to gains and losses due to fluctuations in these currencies. At June 30, 2021, the Company has no exposure to foreign currency risk through accounts payable and accrued liabilities.

11. Capital management

The Company's objective when managing capital resources is to ensure it has sufficient capital to support its ongoing operations including a sufficient level of funds to support continued exploration and development in Namibia and to provide returns for shareholders and benefits for other stakeholders.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the risk characteristics of the Company's assets. The Board of Directors of the Company has not yet made a formal decision to commence the development of Norasa, which decision, remains subject to, amongst other factors, suitable financing arrangements and prevailing market and economic conditions. Management will consider the issue of senior debt, convertible investments, other financial instruments and the introduction of strategic partners as a means to finance development of Norasa while minimizing equity dilution.

As of June 30, 2021, the Company is not subject to any externally imposed capital requirements and there has been no change during the year with respect to the overall capital risk management strategy.

12. Related party transactions

Compensation of key management personnel

Key management personnel as defined under IFRS are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's Chief Executive Officer, Chief Financial Officer and members of the Company's Board of Directors.

Compensation awarded to key management personnel is as follows:

	6 months ended June 30,	
	2021 \$	2020 \$
Director fees	126,402	80,000
Consulting fees	118,087	91,500
Stock-based compensation	2,488,255	_
·	2,732,744	171,500

13. Segment information

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, whose operating results are reviewed regularly by the Company's chief operating decision maker, the Chief Executive Officer and for which discrete financial information is available. The Company has determined that it has one operating segment, the acquisition, exploration and development of uranium and gold mineral properties, all of which are currently located in Namibia. The Company's corporate head office earns nominal interest income which is considered incidental to the activities of the Company and therefore does not meet the definition of an operating segment.

Non-current assets excluding financial assets by geographic area are as follows:

J	73 3 1	June 30, 2021 \$	December 31, 2020 \$
Namibia			
Exploration and evaluation		10,713,600	10,698,359
Investment in associate		2,572,459	2,573,967
		13,286,059	13,272,326